



“As science and technology progress and transform, so too will their need for lawful, long term protection. It is our job to be on top of both for our clients.”

Robert M. Schulman
Partner

PRACTICES

Intellectual Property
Intellectual Property and Life Sciences
Intellectual Property Litigation
Patent

CONTACT

rschulman@hunton.com

Washington, DC

p 202.955.1928

f 202.778.2201

EDUCATION

JD, American University,
Washington College of Law, 1983

BS, Biochemical Engineering,
Rutgers University, with honors,
1980

BAR ADMISSIONS

District of Columbia
US Patent and Trademark Office

Rob's practice focuses on all phases of patent law in the areas of biotechnology, pharmaceuticals and chemical inventions.

Rob's practice focuses on all phases of patent law in the areas of biotechnology, pharmaceuticals and chemical inventions. His major focus is in the area of patent interferences at the patent office and appellate level, for all types of inventions. He has extensive experience in the area of clearance studies for both established and start-up companies, including analysis of validity, infringement and right-to-use.

Rob's practice includes development of patent portfolios, patent prosecution including application drafting, prosecution of applications and appellate review. He also has practice experience with reissues and re-examinations with a special focus in recombinant plant technology, vaccines and drug delivery technology.

Rob is registered with the US Patent and Trademark Office and is a member of the Court of Appeals for the Federal Circuit and Federal Circuit Inn of Courts.

Rob has taught Interference Practice at Georgetown University Law School since 1992.

Relevant Experience

- Established the firm's chemical and life science patent practice.
- Responsible for compilation of patent case data base of Federal Circuit and Board of Appeals and Interferences decisions starting in 1982.
- Successfully developed intellectual property portfolios for both pharmaceutical and biotech companies from inception to product launch and sale of company.
- Conducted numerous due diligence patent reviews, including validity, infringement and right-to-use studies.
- Engaged by numerous companies to train their counsel in best practices for drafting claims and conducting prosecution and interferences.
- Successfully represented companies in using interferences to invalidate competitor's patents in all technologies but with special focus on biotech, plants, medical devices and pharmaceuticals.
- Successfully represented both junior and senior parties in biotech, chemical mechanical and electrical interferences.

- Successfully represented parties in federal court appeals of interference decisions.
- Successfully worked with trial lawyers in major biotech and pharmaceutical district court litigation.
- Representing substantial number of domestic and foreign chemical, pharmaceutical and biotech companies in the areas of plant biotechnology, vaccines, drug delivery, DNA screening methods, receptor binding, computer DNA analysis, and gas processing, and polymers.

Memberships

- Member, American Intellectual Property Association
- Member, American Bar Association
- Member, Intellectual Property Owner's Association
- Member, Biotechnology Industrial Organization
- Member, Federal Circuit Inn of Courts

News

- Robert Schulman on Supreme Court IP Cases, July 11-12, 2011
- Hunton & Williams LLP Issues Annual Biotech Year in Review, March 7, 2008

Alerts

- Is Obviousness Becoming the New Anticipation? How the Federal Circuit is Redrawing the Line Between Anticipation and Obviousness in Favor of Anticipation, September 27, 2012
- Five Things You Should Know About The Replacement of *Inter Partes* Reexamination with *Inter Partes* Review on September 16, 2012, July 26, 2012
- U.S. Patent Office Error in Patent Term Adjustment Calculations May Extend Patent Protections, August 3, 2009

Publications

- Author, Is Obviousness The New Anticipation?, *Law360*, October 2, 2012
- Co-author, 2011 Pharmaceutical, Chemical and Biotech Year in Review,
- Co-author, 2010 Pharmaceutical, Chemical and Biotech Year in Review,
- Co-author, 2009 Pharmaceutical, Chemical and Biotech Year in Review,
- Co-author, 2008 Pharmaceutical, Chemical and Biotech Year in Review,

Events

- Subject-Matter Eligibility In The Wake of *Mayo v. Prometheus*, April 2012
- Developments in Biotechnology, Chemical and Pharmaceutical IP Law, March 8, 2012
- Legislative and Judicial Developments Affecting Patenting of Biotech



Inventions in the United States, DeClerq & Partners IP Seminar, Belgium, November 18, 2011

- Updates on Case Law Relating to Pharmaceutical Inventions, New Jersey Intellectual Property Law Association, November 1, 2010
- Federal Circuit Cases Relating to Patent Interferences, Intellectual Property Owners Meeting, Washington, D.C., November 1, 2008

Awards & Recognition

- Selected for inclusion as a "Best Lawyer," Intellectual Property, *The Best Lawyers in America*, 2010
- Listed as one of top intellectual property attorneys in 2010 in *Virginia Business* magazine
- Listed as one of 20 top intellectual property attorneys in *Washington Post* Survey, 2010 and 2011
- Listed as one of 25 top intellectual property and technology attorneys in the December 2000 issue of *Virginia Business* magazine